InSysBio to present posters at ASCPT 2024 Annual Meeting

November 2019

18 1. 18 Nov 2019 19:58 Course “Modeling for systems biology and biomedicine” at the Faculty of Bioengineering and Bioinformatics This year InSysBio CEO Dr Oleg Demin with expert modelers Tatiana Karelina and Evgeny Metelkin and modelers Dmitry Shchelokov, Svetlana Rubina and Veronika Musatova are giving the course “Modeling for systems biology and biomedicine” at the Faculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University.

25 1. 25 Nov 2019 18:47 PK/RO simulator for anti-PD-1 mAbs InSysBio, a pioneer in Quantitative Systems Pharmacology (QSP), modeling and simulation for drug development, announced the launch of application ‘PK/RO simulator for anti-PD-1 mAbs’. The application is based on the model allowing to predict pharmacokinetics and target binding in human for therapeutic antibodies against PD-1 receptor.

events

Conference

March 6, 2024

InSysBio announces its participation in the ASCPT 2024 Annual Meeting which is to be held March 27-29, at the Broadmoor in Colorado Springs, CO. Tatiana Karelina, Head of Neurodegenerative Diseases modeling team, and Vladislav Leonov, CYTOCON DB team, will present 4 posters by InSysBio in frames of the Meeting, namely:

Thursday, March 28, 2024 5:00 PM – 6:30 PM MDT:

PII-014 "Unraveling IL9 serum distribution patterns: insights from the CYTOCON Database" by Vladislav Leonov, Ekaterina Mogilevskaya, Elita Gerasimuk, Nikolay Pervushin, Nail Gizzatkulov, Oleg Demin
PII-220 "Response to lymphocyte depleting and lymphocyte modulating therapies in different populations of patients with multiple sclerosis investigated by Quantitative Systems Pharmacology model" by Tatiana Karelina, Maria Myshkina, Oleg Demin. The poster will be denoted by a Top Poster Ribbon
PII-221 "Tetravalency impact on bispecific antibody-achieved receptor occupancy and target downregulation: estimation by translational PK/RO model of CTX8371 antibody" by Veronika Musatova, Oleg Demin, Oleg Demin Jr, Dmitry Shchelokov
PII-222 "Validation of a Quantitative Systems Pharmacology model for Chronic Hepatitis B" by Galina Lebedeva¹, Alexander Stepanov¹, Veronika Musatova², Oleg Demin¹, Loveleena Bansal³, Cibele V. Falkenberg³, Valeriu Damian³

Affiliation: (1) InSysBio UK, Edinburgh, UK; (2) InSysBio CY, Paphos, Cyprus; (3) GSK, Collegeville, PA, US

About InSysBio

InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com

←	November 2019	→
Mo	Tu	We	Th	Fr	Sa	Su
				1	2	3
4	5	6	7	8	9	10
11	12	13	14	15	16	17
18 1. 18 Nov 2019 19:58 Course “Modeling for systems biology and biomedicine” at the Faculty of Bioengineering and Bioinformatics This year InSysBio CEO Dr Oleg Demin with expert modelers Tatiana Karelina and Evgeny Metelkin and modelers Dmitry Shchelokov, Svetlana Rubina and Veronika Musatova are giving the course “Modeling for systems biology and biomedicine” at the Faculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University.	19	20	21	22	23	24
25 1. 25 Nov 2019 18:47 PK/RO simulator for anti-PD-1 mAbs InSysBio, a pioneer in Quantitative Systems Pharmacology (QSP), modeling and simulation for drug development, announced the launch of application ‘PK/RO simulator for anti-PD-1 mAbs’. The application is based on the model allowing to predict pharmacokinetics and target binding in human for therapeutic antibodies against PD-1 receptor.	26	27	28	29	30

Upcoming Events